OS Therapies Incorporated (OSTX)
NYSEAMERICAN: OSTX · Real-Time Price · USD
1.880
+0.100 (5.62%)
At close: Aug 13, 2025, 4:00 PM
1.860
-0.020 (-1.06%)
Pre-market: Aug 14, 2025, 9:21 AM EDT
OS Therapies Employees
As of December 31, 2024, OS Therapies had 5 total employees, including 4 full-time and 1 part-time employees. The number of employees increased by 1 or 25.00% compared to the previous year.
Employees
5
Change
1
Growth
25.00%
Revenue / Employee
n/a
Profits / Employee
-$2,654,556
Market Cap
62.86M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5 | 1 | 25.00% |
| Dec 31, 2022 | 4 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
OSTX News
- 7 days ago - OS Therapies Announces Statistically Significant Positive Interim 2-Year Overall Survival Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma - Newsfile Corp
- 7 days ago - OS Therapies Receives Positive Feedback from UK MHRA Scientific Advice Meeting and Submits Innovative Licensing and Access Pathway (ILAP) Request for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma - Newsfile Corp
- 4 weeks ago - OS Therapies Closes $4.2 Million in Warrant Exercise Inducement and Exchange Offer - Newsfile Corp
- 5 weeks ago - OS Therapies Provides Clinical & Global Regulatory Updates - Newsfile Corp
- 6 weeks ago - OS Therapies Granted End of Phase 2 Meeting by US FDA for OST-HER2 Program in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma - Business Wire
- 6 weeks ago - OS Therapies Presents Statistically Significantly Positive 1-Year Event Free Survival, Overall Survival and Safety Clinical Data Updates for OST-HER2 at the MIB Agents Factor Osteosarcoma Conference - Business Wire
- 7 weeks ago - OS Therapies Receives Positive FDA Meeting Feedback on Regulatory Pathway for Accelerated Approval of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma - Business Wire
- 7 weeks ago - OS Therapies Announces Warrant Exercise Inducement & Exchange Offer - Business Wire